There are precious few blogs that examine the relationship between academic researchers and industry. Over at Furious Seasons, there is a lengthy post that discusses Mauricio Tohen, whose name has appeared on many olanzapine (Zyprexa) studies. Tohen is both an academic at Harvard and a scientist at Lilly. According to Philip Dawdy's reporting, the relationship between industry and academia in this case is interesting, to say the least. In order to not steal his thunder, I'll send interested readers to his site.